Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma

BACKGROUND: Several clinical trials have shown that immune treatment focus on programmed death-1 and programmed death-ligand 1 (PD-L1) yields a good clinical efficacy in advanced non-small cell lung cancer (NSCLC). We investigated whether the PD-L1 expression was related to clinicopathologic and mol...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Zhengbo, Yu, Xinmin, Cheng, Guoping, Zhang, Yiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919857/
https://www.ncbi.nlm.nih.gov/pubmed/27342566
http://dx.doi.org/10.1186/s12967-016-0943-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919857/
https://www.ncbi.nlm.nih.gov/pubmed/27342566
http://dx.doi.org/10.1186/s12967-016-0943-4

Ejemplares similares